NasdaqGS - Delayed Quote • USD
Blueprint Medicines Corporation (BPMC)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 15 | 15 |
| Avg. Estimate | -1.66 | -1.48 | -5.55 | -2.78 |
| Low Estimate | -1.8 | -1.63 | -6.28 | -6.46 |
| High Estimate | -1.46 | -1.22 | -4.37 | -0.27 |
| Year Ago EPS | -2.15 | -2.19 | -8.37 | -5.55 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 16 | 16 |
| Avg. Estimate | 80.91M | 92.68M | 392.98M | 596.03M |
| Low Estimate | 72M | 87M | 372M | 481.18M |
| High Estimate | 86.7M | 103M | 449M | 738.9M |
| Year Ago Sales | 63.29M | 45.47M | 249.38M | 392.98M |
| Sales Growth (year/est) | 27.80% | 103.80% | 57.60% | 51.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.67 | -2.54 | -2.37 | -2.04 |
| EPS Actual | -2.15 | -2.19 | -2.2 | -1.82 |
| Difference | 0.52 | 0.35 | 0.17 | 0.22 |
| Surprise % | 19.50% | 13.80% | 7.20% | 10.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.66 | -1.48 | -5.55 | -2.78 |
| 7 Days Ago | -1.66 | -1.48 | -5.55 | -2.78 |
| 30 Days Ago | -1.66 | -1.48 | -5.55 | -2.78 |
| 60 Days Ago | -1.67 | -1.48 | -5.54 | -2.77 |
| 90 Days Ago | -1.72 | -1.44 | -5.42 | -3.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BPMC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.80% | -- | -- | 1.60% |
| Next Qtr. | 32.40% | -- | -- | 10.50% |
| Current Year | 33.70% | -- | -- | 5.20% |
| Next Year | 49.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -92.01% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/10/2024 |
| Reiterates | Needham: Buy to Buy | 2/26/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 2/16/2024 |
| Maintains | Citigroup: Sell to Sell | 2/16/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 2/13/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 1/16/2024 |
Related Tickers
RARE Ultragenyx Pharmaceutical Inc.
42.37
-2.33%
KRYS Krystal Biotech, Inc.
158.53
-3.32%
SWTX SpringWorks Therapeutics, Inc.
40.10
-5.58%
ARGX argenx SE
360.23
+0.51%
BBIO BridgeBio Pharma, Inc.
24.74
-0.84%
PCVX Vaxcyte, Inc.
60.83
+0.35%
IMVT Immunovant, Inc.
28.22
-0.35%
AGIO Agios Pharmaceuticals, Inc.
29.53
+0.34%
ARVN Arvinas, Inc.
34.72
+1.25%
CYTK Cytokinetics, Incorporated
67.55
+0.82%